Home > News > Sosei buys Activus Pharma and drug delivery technology
June 29th, 2010
Sosei buys Activus Pharma and drug delivery technology
Abstract:
Sosei has revealed its intention to acquire Activus Pharma in a deal which allows the Japan-based firm to get their hands on Activus' nanoparticle drug formulation tools, a technology that's in its infancy but holds great potential.
According to market research firm Cientifica, the market for nanotechnology-enabled drug delivery will rise to $26bn by 2012 from its current size of $3.4bn, representing a compound annual growth rate of 37 per cent.
The firm also predict the market could steeply rise after 2012, reaching potentially $220bn by 2015 for these nano-enabled compounds.
Source:
in-pharmatechnologist.com
Bookmark:
| Related News Press |
News and information
Quantum computer improves AI predictions April 17th, 2026
Flexible sensor gains sensitivity under pressure April 17th, 2026
A reusable chip for particulate matter sensing April 17th, 2026
Detecting vibrational quantum beating in the predissociation dynamics of SF6 using time-resolved photoelectron spectroscopy April 17th, 2026
Nanomedicine
A fundamentally new therapeutic approach to cystic fibrosis: Nanobody repairs cellular defect April 17th, 2026
New molecular technology targets tumors and simultaneously silences two ‘undruggable’ cancer genes August 8th, 2025
New imaging approach transforms study of bacterial biofilms August 8th, 2025
Electrifying results shed light on graphene foam as a potential material for lab grown cartilage June 6th, 2025
Announcements
A fundamentally new therapeutic approach to cystic fibrosis: Nanobody repairs cellular defect April 17th, 2026
UC Irvine physicists discover method to reverse ‘quantum scrambling’ : The work addresses the problem of information loss in quantum computing system April 17th, 2026
Nanobiotechnology
A fundamentally new therapeutic approach to cystic fibrosis: Nanobody repairs cellular defect April 17th, 2026
New molecular technology targets tumors and simultaneously silences two ‘undruggable’ cancer genes August 8th, 2025
New imaging approach transforms study of bacterial biofilms August 8th, 2025
Electrifying results shed light on graphene foam as a potential material for lab grown cartilage June 6th, 2025
Acquisitions/Mergers/Splits
180 Degree Capital Corp. Life Science Portfolio Company Enters Into Definitive Agreement to be Acquired May 6th, 2020
180 Degree Capital Corp.’s Portfolio Company, Synacor, Inc., Agrees to Merge with Qumu Corporation in All-Stock Transaction February 11th, 2020
Combination of Nanometrics and Rudolph Technologies to Create Onto Innovation October 16th, 2019
 |
||
 |
||
| The latest news from around the world, FREE | ||
 |
||
|
|
||
| Premium Products | ||
 |
||
|
Only the news you want to read!
Learn More |
||
 |
||
|
Full-service, expert consulting
Learn More |
||
|
|
||